knowledge -WSS

knowledge

author：explore 2025-09-06 03:32:38 - browse：215

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Astellas still sees hope in its gene therapy after four deaths

WSS

Morphosys mixed study results for blood cancer drug

Pregnant women don't need prenatal multivitamins, study concludes

Congress must reauthorize a committee to support older Americans

Ransomware attacks on hospitals: Study outlines patient impact

Hospitals look to new technology to keep health care workers safe

David Sabatini, ex

leisure time

knowledge

explore

ChatGPT in medicine: STAT answers readers' burning questions

Why Talkspace is targeting Medicare, a tricky market

After affirmative action ruling, medical educators look to 'holistic review'

Gain of function research would be limited under House proposal

Affirmative action in medical school literally saved lives

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Biden's 'march

Moonlake's readout produced a cash windfall. Risks remain

Florida health officials providing scant details on measles cases

explore

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

CRISPR pioneers react to Casgevy, first gene

Morphosys mixed study results for blood cancer drug

Stem cell biologist probes earliest stages of human development

$1 billion proposal to grow Boston, Massachusetts biotech

Stem cell biologist probes earliest stages of human development

leisure time

hotspot

explore

leisure time